Please login to the form below

Not currently logged in
Email:
Password:

ATTR cardiomyopathy

This page shows the latest ATTR cardiomyopathy news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

Eplontersen is designed to reduce the production of transthyretin (TTR) protein to treat amyloid transthyretin (ATTR), a systemic, progressive and fatal disease. ... It is currently in global phase 3 trials for ATTR cardiomyopathy (ATTR-CM) and ATTR

Latest news

  • Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn

    Initially, Novo will focus on the clinical development of Prothena’s antibody PRX004 in ATTR cardiomyopathy. ... Initially, Novo will focus on the clinical development of Prothena’s antibody PRX004 in ATTR cardiomyopathy, an underdiagnosed and

  • Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

    placebo in patients with ATTR cardiomyopathy, reducing the death rate from around 43% to 29.5%. ... Prior to Vyndaqel, treatment options for patients with ATTR cardiomyopathy were restricted to symptom management and – in rare cases – a heart

  • Vyndaqel a bright spot as Pfizer comes under pressure Vyndaqel a bright spot as Pfizer comes under pressure

    following its FDA approval to treat ATTR cardiomyopathy last September. ... As of the end of 2019 more than 9, 000 ATTR cardiomyopathy patients had been diagnosed in the US – raising the diagnosis rate from 1% pre-Vyndaqel launch to around 9%,

  • Pfizer buys dwarfism drug company Therachon for $810m Pfizer buys dwarfism drug company Therachon for $810m

    The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)

  • Speedy approval for Pfizer's Onpattro rival Speedy approval for Pfizer's Onpattro rival

    Approved in two different formulations. Pfizer’s blockbuster-in-waiting drug tafamidis has gained FDA approval to treat cardiomyopathy in patients with rare disease ATTR. ... Cardiomyopathy (CM) is the most serious of the symptoms seen in patients with

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
11 London

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....